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theBACKGROUND Familial forms of primary sinus bradycardia have sometimes been attributed to mutations in HCN4,
SCN5A, and ANK2. In these studies, no structural cardiac alterations were reported in mutation carriers. However, a
cluster of reports in the literature describe patients presenting with sinus bradycardia in association with left ventricular
noncompaction cardiomyopathy (LVNC), pointing to a shared genetic cause.
OBJECTIVES This study sought to identify the genetic defect underlying the combined clinical presentation of
bradycardia and LVNC, hypothesizing that these 2 clinical abnormalities have a common genetic cause.
METHODS Exome sequencing was carried out in 2 cousins from the index family that were affected by the combined
bradycardia–LVNC phenotype; shared variants thus identiﬁed were subsequently overlaid with the chromosomal regions
shared among 5 affected family members that were identiﬁed using single nucleotide polymorphism array analysis.
RESULTS The combined linkage analysis and exome sequencing in the index family identiﬁed 11 novel variants shared
among the 2 affected cousins. One of these, p.Gly482Arg in HCN4, segregated with the combined bradycardia and LVNC
phenotype in the entire family. Subsequent screening of HCN4 in 3 additional families with the same clinical combination
of bradycardia and LVNC identiﬁed HCN4 mutations in each. In electrophysiological studies, all found HCN4 mutations
showed a more negative voltage dependence of activation, consistent with the observed bradycardia.
CONCLUSIONS Although mutations in HCN4 have been previously linked to bradycardia, our study provides the ﬁrst
evidence to our knowledge that mutations in this ion channel gene also may be associated with structural abnormalities
of the myocardium. (J Am Coll Cardiol 2014;64:745–56) © 2014 by the American College of Cardiology Foundation.m the *DepartmentofClinicalandExperimentalCardiology,AcademicMedicalCenter,Amsterdam,theNetherlands;yDepartmentof
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746S inus bradycardia, arbitrarily deﬁned asa heart rate lower than 60 beats/min,can occur at any age and in a variety
of cardiac diseases (1). Although familial
forms of primary sinus bradycardia are recog-
nized, they have been attributed to muta-
tions in HCN4 (2–4), SCN5A (5,6), and ANK2
(7). In these studies, no structural cardiac
alterations were reported in mutation car-
riers. However, a cluster of reports in the
literature describe patients presenting with
sinus bradycardia in association with left
ventricular noncompaction cardiomyopathy
(LVNC) (8–11), raising the possibility that
these 2 defects could have a common cause.SEE PAGE 768LVNC is an increasingly recognized car-
diomyopathy characterized by a noncom-
pacted left ventricular myocardial layer with
numerous trabeculations and deep inter-trabecular recesses (12,13). These clinical manifesta-
tions may be highly variable. LVNC may occur in
isolation; however, besides sinus bradycardia, it may
present together with structural congenital heart de-
fects, neuromuscular disorders, or mitral valve ab-
normalities (13,14). LVNC may be associated with
heart failure, (potentially) lethal arrhythmias, and
systemic embolic events. It may be sporadic or fa-
milial, and thus far, has mainly been associated with
mutations in genes encoding sarcomere proteins
(TMP1, MYH7, ACTC1, TNNT2, and MYBPC3) (10,15–
17), although mutations in other genes have also
been reported: TAZ (18), DTNA (19), LDB3 (20), TNNI3,
PLN (21), and LMNA (22). Most recently, mutations
were identiﬁed in MIB1 (23) and RYR2 (24).
In this study, we characterized a large Dutch family
presentingwith sinus bradycardia in combinationwith
other cardiac abnormalities, including LVNC. In an
effort to identify the causal genetic defect underlying
this combined phenotypic manifestation in this fam-
ily, we integrated exome sequencing with linkage
analysis, and identiﬁed a novel mutation in HCN4.
HCN4 encodes the hyperpolarization-activated cyclic
nucleotide-gated channel 4, which conducts the
hyperpolarization-activated “funny” current (If), in
the sinoatrial node (SAN) (25,26). In linewith the role oflationships relevant to the contents of this paper to disclose. M
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
o listen to this issue’s audio summary by JACC Editor-in-Chief D
received May 12, 2014; accepted May 21, 2014.this current in SAN pacemaker activity, mutations in
HCN4 have been reported as a cause of sinus brady-
cardia (2–4). However, the association between HCN4
mutations and structural cardiac alterations has never
been described before. To conﬁrm our results, we
subsequently screened HCN4 in 3 additional families
with the same clinical combination of bradycardia
and LVNC and have identiﬁedHCN4mutations in all 3.
METHODS
FAMILY A. In the index family, 7 individuals within 2
generations were affected with bradycardia in com-
bination with LVNC (Fig. 1). Available data on medical
history, physical examination, 12-lead electrocardio-
gram (ECG), echocardiography, Holter monitoring,
and exercise testing were collected. Genomic deoxy-
ribonucleic acid (DNA) was extracted from peripheral
blood according to standard procedures. Written
informed consent was obtained from all participating
family members.
ECHOCARDIOGRAPHY. Two cardiologists blinded to
the described phenotype and to the HCN4 mutation
status analyzed the echocardiographic images. LVNC
was called as present or absent by criteria described
previously (27,28). Ejection fractions were calcu-
lated using the Teichholz M-mode method (Table 1).
LINKAGE ANALYSIS. Genome-wide single nucleotide
polymorphism (SNP) genotyping was carried out in
5 individuals (II:1, II:3, II:9, III:2, and III:4) from
family A, presenting with bradycardia and LVNC us-
ing the Illumina HumanOmni2.5 array (Illumina,
San Diego, California). Genotypic data were used
for linkage analysis to identify chromosomal regions
shared among affected individuals. Patient II:6 was
excluded from the linkage analysis because at the
time of our study, he had persistent atrial ﬁbrillation,
and his sinus rhythm could therefore not be assessed
(29). Patient II:7 joined the study at a later stage.
Linkage analysis was performed using the interface
easyLinkage V5.08 (30) running Merlin 1.1.2 (31), with
the assumption of an autosomal dominant inheri-
tance pattern, a disease allele frequency of 0.001, and
a disease penetrance of 0.9. Mendelian inheritance
was checked using PedCheck 1.1 (32). Gene frequency
was assumed to be equal between males and females.s. Milano and Dr. Vermeer contributed equally to
ntin Fuster.
r. Valentin Fuster.
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FIGURE 1 Pedigree of Family A
Squares/circles indicate male/female family members, respectively; open symbols repre-
sent unaffected persons; symbols with a slash represent deceased persons; solid left half:
affected with bradycardia, solid right half: left ventricular noncompaction cardiomyopathy
(LVNC), gray: undetermined. The proband (II:1) is indicated by the arrow. HCN4
p.Gly482Arg mutation carriers are indicated by a plus sign. The numbers below the
subject symbol denote the identiﬁcation of the family members used in the text.
J A C C V O L . 6 4 , N O . 8 , 2 0 1 4 Milano et al.
A U G U S T 2 6 , 2 0 1 4 : 7 4 5 – 5 6 HCN4 Mutations in Patients With Bradycardia & LVNC
747EXOME SEQUENCING. Exome sequencing was car-
ried out on 2 genetically distant family members
(cousins III:2 and III:4) at the Beijing Genomics
Institute (BGI, Beijing, China). The coding region of
the genome was captured using the Agilent Sure-
Select Target Enrichment system (Agilent Technolo-
gies, Santa Clara, California), followed by sequencing
on the Illumina HiSeq 2000 platform. The SOAPsnp
(for single nucleotide variants) and the GATK (for
copy number variants) genome analysis algorithms
were used for genotype calling (33,34). Variants were
compared using publicly available variant databases—
namely: 1) dbSNP132; 2) Exome Variant Server,
NHLBI GO Exome Sequencing Project (ESP), Seattle,
Washington); 3) Phase 1v3 of the 1,000 Genomes
project (data release 10/2012); 4) Genome of the
Netherlands (GoNL) (35); and 5) the 69 genomes from
Complete Genomics (Mountain View, California)—in
addition to 15 in-house exome datasets, using KNIME
open-source software version 2.1 with the Knime4Bio
plugin (36). Genetic variants found in any of these
databases were excluded from further analysis. The 2
exomes were subsequently compared, and genetic
variations found in both patients were retained.
Variants that remained after ﬁltering were validated
by Sanger sequencing and were tested for segregation
with the combined (bradycardia–LVNC) phenotype in
the family (e.g., testing for presence in all affected
and absence in all unaffected family members).
SEQUENCING OF HCN4 IN ADDITIONAL FAMILIES. The
HCN4 gene (Ensembl Transcript ID ENSG0000013
8622) was screened for coding region mutations in 3
additional families by polymerase chain reaction
ampliﬁcation of the coding regions followed by
Sanger sequencing. Primer sequences are available
upon request. Segregation analysis of HCN4 muta-
tions in the families was carried out by Sanger
sequencing with the exception of the c.1241C>G in
family C, which was done by restriction fragment
length polymorphism analysis using HaeII (New En-
gland Biolabs, Ipswich, Massachusetts).
MUTATION ANALYSIS OF GENES PREVIOUSLY
ASSOCIATED WITH LVNC. The following genes pre-
viously associated with LVNC were screened for mu-
tations in the 4 probands (families A through D):
TMP1, MYBPC3, ACTC1, MYH7, LDB3, DTNA, TNNT2,
TNNI3, PLN, TAZ, LMNA, RYR2, and MIB1. The coding
region and splice sites of these genes were screened
for the presence of novel or rare variants. The MIB1
gene was screened by polymerase chain reaction–
Sanger sequencing. All other genes were screened
by next-generation sequencing. For next-generation
sequencing, coding exons were captured from 200 ngof genomic DNA using the Agilent HaloPlex Target
Enrichment system (Agilent Technologies) following
the manufacturer’s protocol. Sequencing was carried
out on a MiSeq sequencer (Illumina) for 150-bp paired-
end read sequencing. Sequence reads were aligned to
the human reference genome (standard 1000 Genomes
fasta GRCh37 alignment ﬁle) using BWA (version 0.6.2)
(37) and called using GATK (version 2.6) (34) and
SAMtools (version 0.1.19) (38). The mean depth was
171, and 97.8% of the targeted regions were covered
at least 10 times. The Knime4Bio tool was used to
manage and ﬁlter variants (36). Synonymous varia-
tions thatwerenot located at splice siteswere excluded
from further analysis. Heterozygote and homozygote
coding and splice site variations of each sequenced
patient were compared with publicly available variant
databases, namely: 1) dbSNP137, common variant;
2) Phase 1v3 of the 1000 Genomes project (data
release 10/2012); 3) NHLBI GO Exome Sequencing
Project (ESP, Seattle, Washington); 4) GoNL (35); and
5) the 69 genomes from Complete Genomics.
HAPLOTYPE ANALYSIS IN FAMILIES B AND D. We
carried out haplotype analysis to check whether
theHCN4 c.1441T>Cmutation in families B andDhad a
common origin. Ten microsatellite markers ﬂanking
HCN4 were selected (D15S967, D15S981, D15S1050,
D15S980, D15S204, D15S211, D15S1041, D15S206,
D15S115, and D15S154) and typed in individuals from
these families. Primer sequences of all markers were
obtained from the UniSTS database. Genomic DNAwas
ampliﬁed in the presence of FAM, and fragments were
separated on an ABI3500 genetic analyzer (Applied
TABLE 1 Clinical Dat
Patient #
Age
(yrs)
A-II:1 57
A-II:3 55
A-II:4 54
A-II:6 54
A-II:7 49
A-II:9 47
A-II:10 42
A-II:11 45
A-III:2 20
A-III:4 16
B-II:5 54
C-II:4 74
C-III:1 44
C-III:2 42
D-II:4 NA
D-III:2 36
*Numbering for the site of
report shows extreme brad
AF ¼ atrial ﬁbrillation; EF
LAEDV ¼ left atrial end dia
assessed; OHCA ¼ out-of-h
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748Biosystems, Foster City, California). Results were
processed with GeneMapper software 4.1 (Applied
Biosystems).
COMPLEMENTARY DNA CONSTRUCTS, MUTAGENESIS,
AND HETEROLOGOUS EXPRESSION. The construct
(pcDNA3.1) containing wild-type (WT) hHCN4 com-
plementary DNA (cDNA) was described before (39).
The c.1241C>G (p.Ala414Gly) point mutation was
introduced into the WT hHCN4 cDNA by site-directed
mutagenesis (QuikChange kit, Stratagene, Agilent
Technologies). The hHCN4 cDNAs containing the
mutants c.1441T>C (p.Tyr481His) and c.1444G>C
(p.Gly482Arg) were synthesized at Life Technologies
(Carlsbad, California) and subsequently cloned into
pcDNA3.1.
Chinese hamster ovary (CHO) (Sigma-Aldrich, St.
Louis, Missouri) cells were cultured in Ham’s F-12
medium with 2 mmol/l glutamine, 10% fetal bovine
serum (Lonza, Basel, Switzerland), 1% P/S (5,000 U/ml
penicillin and 5,000U/ml streptomycin sulfate, Lonza)
in 5% CO2 at 37C. CHO cells were transiently trans-
fected with 2 mg of WT-HCN4 cDNA or, to recapitulate
the heterozygous state, 1 mg of WT and 1 mg of
mutant HCN4 construct, using lipofectamine (Gibco
BRL, Life Technologies). Successfully transfected
cells were visualized by coexpressed green ﬂuores-
cent protein (GFP) (0.5 mg eGFP plasmid) (pcDNA3-
eGFP, Life Technologies).
WHOLE-CELL-PATCH ELECTROPHYSIOLOGICAL
RECORDINGS AND ANALYSIS. HCN4 currents werea of the Families Analyzed in This Study
Min HR Max HR
Average
HR
Site of
Noncompaction*
EF
(%)
31 107 62‡ 1, 2 60 OHCA (57 y
30 103 44 1, 2 64 ICD advised
38 103 63 0 62
48 175 85 1 38 MV reconst
NA NA NA 1, 2 70 MV reconst
33 102 46 1, 2 61 Pacemaker
NA NA NA 0 51
NA NA NA 0 50 OHCA (39 y
15 126 46 1, 2 50 Pacemaker
26 110 41 1, 2 73 Pacemaker
28 94 50 1, 2 40 AF, myxoid
32 169 66 1, 2 30 AF, ICD wit
NA NA NA 1 70 LV hypertro
30 111 55 1, 2 70 LV hypertro
NA NA NA NA NA Pacemaker
27 92 44 1, 2 41 Pacemaker
noncompaction: none ¼ 0, left ventricular apex¼ 1, right ventricular involvement ¼ 2. †The n
ycardia.
¼ ejection fraction; HR ¼ heart rate; ICD ¼ implantable cardioverter deﬁbrillator; IVS ¼ inte
stolic volume indexed for body surface area; LVIDd ¼ left ventricular internal diastolic dimen
ospital cardiac arrest.recorded 2 days after transfection at 37  0.2C using
the amphotericin-perforated patch-clamp technique
(Axopatch 200B ampliﬁer, Molecular Devices, Sun-
nyvale, California). Signals were low-pass ﬁltered
(cutoff frequency 5 kHz) and digitized at 5 kHz. Series
resistance was compensated by 70% to 80%, and
potentials were corrected for the estimated liquid
junction potential. Voltage control, data acquisition,
and analysis were accomplished using custom soft-
ware. Superfusion solution contained (in mmol/l):
NaCl 140, KCl 5.4, CaCl2 1.8, MgCl2 1.0, glucose 5.5,
HEPES 5.0 (pH 7.4) (NaOH). Pipettes (borosilicate
glass; resistance 2 to 2.5 MU) were ﬁlled with solution
containing (in mmol/l): K-gluc 125, KCl 20, NaCl 10,
amphotericin-B 0.88, HEPES 10 (pH 7.2) (KOH).
Cell membrane capacitance (7.6  0.6 pF [average 
SEM, n ¼ 35]) was estimated by dividing the decay
time constant of the capacitive transient in response
to 5 mV hyperpolarizing voltage clamp steps
from 20 mV by the series resistance.
HCN4 currents were evoked by hyperpolarizing
steps (range 20 to 160 mV, increments of 10 mV)
from a holding potential of 0 mV. To prevent mem-
brane instability and cell death at very negative
potentials, the duration of the voltage steps was
progressively reduced from 12 s (at 20 mV) to 1.5 s
(at 160 mV). The voltage step durations were sufﬁ-
cient to reach steady-state activation at all voltages,
because activation kinetics of HCN4 channels become
faster atmore negative potentials (40). Tail currents (atMedical History† IVSd LVIDd LVPWd LAEDV
rs), ICD with pacing capacity 15 46 12 21.6
11 51 8 31.2
11 60 10 24.4
ruction, maze 10 68 12 71.0
ruction, maze, OHCA 9 53 10 30.7
11 46 6 19.1
9 46 8 30.7
rs), ICD with pacing capacity 8 60 7 29.3
11 47 8 17.8
11 56 12 25.2
mitral valve, pacemaker 8 54 9 55.0
h pacing capacity 9 49 13 26.9
phy (IVS ¼ 13 mm) 13 NA 13 23.3
phy (IVS ¼ 13 mm) 13 55 11 35.1
NA NA NA NA
11 75 11 22.1
umber in parentheses indicates the patient’s age in years at the time of OHCA. ‡Holter
rventricular septum; IVSd ¼ interventricular septum in diastole; LV ¼ left ventricular;
sion; LVPWd ¼ left ventricular posterior wall in diastole; MV ¼ mitral valve; NA ¼ not
TABLE 2 Overview of Known Human HCN4 Mutations
Residue
Change
HCN4 Domain
Position Patients’ Clinical Characteristics
HCN4
Domain (Ref. #)
p.Ala195Val Cytoplasmic Sinus bradycardia in sudden infant
death syndrome
(51)
p.Gly482Arg Pore Family A This study
p.Tyr481His Pore Families B and D This study
p.Ala414Gly S4–S5 linker Family C This study
p.Ile404fs Extracellular S5–pore ST-segment elevation and complete
right bundle branch block
(52)
p.Gly480Arg Pore Sinus bradycardia (4)
p.Ala485Val Pore Sinus bradycardia (3)
p.Lys530Asn C-linker Tachycardia-bradycardia
syndrome and AF
(53)
p.Asp553Asn C-linker Sinus bradycardia with torsade de
pointes ventricular tachycardia
(54)
p.Pro544fs C-linker Sinus bradycardia (6)
p.Ser672Arg cAMP binding domain Sinus bradycardia (55)
p.Thr644fs cAMP binding domain Sinus bradycardia with premature
beats linked to adrenergic stress
(56)
p.Val759Ile Cytoplasmic Sinus bradycardia in sudden infant
death syndrome
(51)
AF ¼ atrial ﬁbrillation; cAMP ¼ cyclic adenosine monophosphate.
FIGURE 2 Typical ECG Showing the Bradycardia in Family A
The electrocardiogram (ECG) is from a Holter recording of III:2, family A.
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7490 mV), plotted against test voltage, provided the
activation-voltage relationship; the latter was
normalized bymaximumamplitude and ﬁttedwith the
Boltzmann function: I/Imax ¼ A/{1.0 þ exp[(V–V1/2)/k]}
to determine the half-maximum activation voltage
(V1/2) and slope factor (k).
STATISTICAL ANALYSIS. Data are mean  SEM.
Groups were compared using 1-way analysis of vari-
ance followed by Tukey’s test or 2-way repeated
measures analysis of variance followed by pairwise
comparison using the Student-Newman-Keuls test.
A p value of <0.05 deﬁned statistical signiﬁcance.
RESULTS
FAMILY A. The pedigree of the index family is shown
in Figure 1. The proband (II:1) visited our cardio-
genetics outpatient clinic because of an out-
of-hospital cardiac arrest (OHCA) as a result of
ventricular ﬁbrillation at the age of 57 and a positive
family history for cardiomyopathy. A previously
made Holter recording showed episodes of brady-
cardia for 7% of the 24 h, with a minimum heart rate
of 31 beats/min. Further evaluation initially did
not reveal any abnormalities, and an implantable
cardioverter-deﬁbrillator (ICD) (with pacing capacity)
was implanted for secondary prevention of sudden
cardiac death. LVNC of the myocardium was detected
after evaluation of her echocardiographs.
Three siblings (II:3, II:7, and II:9) and 2 nephews
(III:2 and III:4) of the proband presented with the
same combination of bradycardia and LVNC. Anam-
nestically, the sinus bradycardia of III:2 was ﬁrst
detected in utero during Doppler echocardiographic
evaluation. A pacemaker was implanted in II:7, II:9,
and III:2, because of bradycardia-related symptoms.
Clinical data of family A are presented in Table 1.
Two individuals (II:6 and II:7) had mitral valve
reconstruction because of a mitral valve prolapse.
Post-operative atrial ﬁbrillation occurred in II:6, and
he was unsuccessfully treated by a surgical maze
procedure; consequently, we could not determine
the occurrence of bradycardia in this individual (29).
His echocardiogram showed LVNC. In 2013, II:7
collapsed during breakfast; he regained conscious-
ness after 1 to 2 min and was admitted to the hospital.
The ECG record showed atrial ﬁbrillation. Later, a
sinus rhythm with a total atrioventricular block,
without an adequate escape rhythm, was observed.
Given his LVNC, worsening systolic function with
signs of progressive conduction disorders, and the
expectation of frequent pacing, his pacemaker was
replaced by a biventricular ICD. Cardiac evaluation
of II:4 and II:10 did not reveal any abnormalities.The youngest sister of the proband (II:11) had an
OHCA at 39 years old as a result of ventricular ﬁbrilla-
tion. During her hospital admission, she was repeat-
edly deﬁbrillated because of sustained polymorphic
ventricular tachycardias, initiated by short-coupled
ventricular extrasystole. After an electrophysiology
study, in which a right bundle branch block mor-
phology with extreme axis focus was ablated, no
further arrhythmias were observed. Echocardio-
graphic investigation did not reveal signs of cardio-
myopathy. The parents of the proband, who were
distantly related (seventh-degree relatives), are
deceased, and no clinical information was available.
I:1
I:1
I:1 I:2
I:2
I:2
II:1
? ? ?
?
?
Family B
Family C
Family D
III:1
III:1 III:2
III:1 III:2
III:2
II:2 II:3
II:1
II:1
II:2
II:2 II:3
II:3
II:4
II:4
II:4
II:5
+
+
+
+ +
+
+
II:5 II:6 II:7 II:8
FIGURE 4 Additional Families With Sinus Bradycardia
and LVNC
HCN4 mutation carriers are indicated by a D: p.Tyr481His in
family B and D, p.Ala414Gly in family C. Description of symbols
as in Figure 1. LVNC ¼ left ventricular noncompaction
cardiomyopathy.
FIGURE 3 Echocardiographic Image of An Affected Individual (III:4) With
LVNC and Bradycardia
End-systolic apical 4-chamber view shows left ventricular noncompaction cardiomyopathy
(LVNC) (A), apical 4-chamber view with color Doppler image shows deep recesses ﬁlled
with blood from the left ventricular cavity at end-diastole (B), apical 2-chamber view (C),
and short-axis view (D). Note the widespread prominent left ventricular trabeculations and
deep intertrabecular recesses extending into the mid-ventricular portion of the inferior
wall in the affected patient. See accompanying Online Videos 1, 2, and 3.
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750Representative ECG traces are presented in Figure 2
(III:4). Representative echocardiographic ﬁndings of
an affected family member (III:4) are presented in
Figure 3 and Online Videos 1, 2, and 3.
GENOME-WIDE LINKAGE ANALYSIS. We set out to
identify the genetic defect underlying the combined
phenotype of bradycardia and LVNC. Although the
parents are distantly related, the pedigree of family
A is suggestive of an autosomal dominant pattern of
inheritance. Linkage analysis in 5 relatives with
combined bradycardia and LVNC was performed.
All loci with suggestive linkages were checked for
sharing in all 5 individuals by haplotype analysis; we
thus uncovered 30 loci that were shared among
all affected individuals (Online Fig. 1). In total, these
shared regions span w492 Mb and contain >2,000
coding genes.
EXOME SEQUENCING. Exome sequencing was car-
ried out on cousins III:2 and III:4 in family A.
Coverage and quality scores of the exome sequencing
experiment are shown in Online Table 1. The number
of exonic variants identiﬁed per sequenced individ-
ual is shown in Online Table 2. We identiﬁed 72 novel
shared variants not previously reported in public
variant databases, including the ethnically matched
GoNL study (35). We overlaid these variants with
the 30 linkage regions, thus narrowing the list downto 11 novel shared variants (Online Table 3). Of these,
only 1 variant in HCN4 (c.1444G>C, p.Gly482Arg)
cosegregated with the combined phenotype in the
remaining affected family members and was absent in
all unaffected family members. Subject II-6, who had
LVNC, but in whom the presence of sinus bradycardia
could not be evaluated, carried the mutation.
ADDITIONAL FAMILIES: PEDIGREES. To further
explore the possible link between mutations in HCN4
and the combined phenotype of bradycardia and
LVNC, we screened HCN4 in 3 additional families
with this combined clinical presentation. The pedi-
gree of families B, C, and D are shown in Figure 4.
FAMILY B. The proband of family B (individual II:5)
was referred to the cardiologist after she collapsed
in the shower. The cardiovascular examination
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FIGURE 5 Haplotype Analysis of 10 Microsatellite Markers at the HCN4 Locus in
Families B and D, With the p.Tyr481His Mutation in HCN4
The haplotype containing the HCN4mutation is colored red. Markers D15S206 and D15S115
ﬂanking the recombination event telomeric of the mutation are 200 kB apart.
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751revealed bradycardia, LVNC, and a myxoid degener-
ation of the mitral valve. Moreover, polymorphic
ventricular extrasystoles occurred during exercise. A
few months later, she presented with atrial ﬁbrilla-
tion at age 53 years. A loop recorder showed more
than 800 episodes of bradycardia in 64 days (heart
rate <30 beats/min). Because of the syncope and the
frequent episodes of bradycardia, a pacemaker was
implanted. Her son also presented with the combined
phenotype. Both were carriers of a mutation in HCN4
(c.1441T>C, p.Tyr481His).
FAMILY C. The proband of family C (individual II:4)
is a 74-year-old man who presented with atrial
ﬁbrillation; echocardiographic evaluation revealed
LVNC. His 2 sons, presented with the combined
phenotype of LVNC and bradycardia. On Holter
monitoring, 1 displayed severe sinus bradycardia
involving 12 episodes of standstill with a maximum
duration of 2.88 s, which most of the time occurred
during episodes of bradyarrhythmia. All 3 carried a
mutation in HCN4 (c.1241C>G, p.Ala414Gly).
FAMILY D. The proband of family D (individual III:2)
has been previously described in a case report (10).
A 36-year-old man was referred because of progres-
sive fatigue. Cardiovascular examination revealed
a severe sinus bradycardia (40 beats/min), LVNC,
and moderate aortic valve regurgitation. His mother
(D:II:4) has a pacemaker because of bradyar-
rhythmias. Echocardiographic reports of the mother
were not available. The HCN4 mutation (c.1441T>C,
p.Tyr481His) that was found in family B was identi-
ﬁed in the proband and his mother.
To determine whether the c.1441T>C mutation of
families B and D had a common origin, we investi-
gated the haplotype harboring this mutation in the
2 families. This provided evidence of a common
ancestral haplotype (Fig. 5).
None of the mutations identiﬁed in this study
were found in large sets of the general population,
including 6,503 individuals from the Exome Variation
Database NHLBI GO Exome Sequencing Project
(ESP, Seattle,Washington) and 500 ethnicallymatched
(Dutch) controls from the GoNL project. The 3 HCN4
mutations identiﬁed in this study are presented in
Figure 6. They affect residues fully conserved among
98 species from lamprey to human (data not shown).
ADDITIONAL GENETIC ANALYSIS. To ensure that
the LVNC phenotype in families A through D was not
due to mutations in any of the known LVNC genes,
the probands from these families were screened for
mutations in these genes. No novel or rare (minor
allele frequency <1%) mutations in the known LVNC
genes were found.ELECTROPHYSIOLOGY OF MUTANT HCN4 CHANNELS.
WT and mutant HCN4 channels were transiently
expressed in CHO cells, and the biophysical proper-
ties were examined using the voltage clamp protocol
as depicted in Figure 7A, top panel. Tail currents
(Fig. 7A, bottom, inset) were used to analyze the
voltage dependence of activation (Fig. 7B, left panel).
Half-maximal activation voltages (V1/2) in all mutant
HCN4 channels were signiﬁcantly more negative
as compared with WT channels, whereas no differ-
ences in slope factor (k) were observed (Fig. 7B,
right panels). The current density at 160 mV, the
potential at which all groups in all channels are acti-
vated (Fig. 7B, left panel), did not differ signiﬁcantly,
although there is a tendency to smaller densities
(Fig. 7C, left panel) (184  35 pA/pF [WT, n ¼ 11],
120  30 pA/pF [WTþp.Ala414Gly, n ¼ 9], 100  18
pA/pF [WTþp.Tyr481His, n ¼ 8], and 97  21 pA/pF
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FIGURE 6 Overview of the Protein Changes in HCN4
(A) Schematic diagram of the HCN4 mutation locations with respect to the channel
domains. (B) Structural model of HCN4 channel obtained from a ribbon SwissProt model
of amino acids 264–520. Positions of the mutated amino acids are indicated by hydrogen
bonds. Arrows show the locations of the novel HCN4 mutations identiﬁed in this study.
(C) p.Ala414Gly, p.Tyr481His, and p.Gly482Arg are evolutionary conserved amino acid
residues.
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752[WTþp.Gly482Arg, n¼ 7]). However, as a consequence
of the shifts in voltage dependence of activation, the
current density of all mutant HCN4 channels was
signiﬁcantly lower, at 60 mV and 50 mV (Fig. 7C,
right panels), for example, in the voltage range of
diastolic depolarization of human SANpacemaker cells
(Figs. 7B and 7C, gray area) (25). The lower current
densities of the mutant HCN4 channels in the voltage
range of human SAN diastolic depolarization are
consistent with the bradycardia observed in the
patients.
DISCUSSION
For the ﬁrst time, we provide strong evidence linking
mutations in HCN4 to the combined clinicalpresentation of bradycardia and LVNC. Using a
strategy entailing linkage analysis and exome
sequencing, we ﬁrst identiﬁed the causal HCN4
mutation in a large pedigree with individuals
affected by the combined phenotype. Follow-up
screening of HCN4 in 3 other families with the
same combined clinical presentation uncovered 2
additional HCN4 mutations in the 3 families.
Although mutations in HCN4 have been previously
linked to bradycardia (Table 2), our study provides
the ﬁrst evidence to our knowledge that mutations
in this ion channel gene also may be associated with
structural abnormalities of the myocardium.
HCN4 encodes the fourth isoform of the
hyperpolarization-activated cyclic nucleotide-gated
channel 4, which conducts the hyperpolarization-
activated “funny” current, among others in the SAN
(25,26). In line with the role of this current in SAN
pacemaker activity, the HCN4 locus has been identi-
ﬁed as a modulator of heart rate in a recent genome-
wide association study (41), and mutations in HCN4
have been reported as a cause of sinus bradycardia
(2–4). None of these studies, however, describe
structural cardiac alterations, although it is unclear
whether patients involved were actively screened
for this.
The HCN4 channel is composed of 6 trans-
membrane domains and a pore-forming loop—the P
domain—located between transmembrane domains
S5 and S6, acting as the ion conducting pore and
selectivity ﬁlter (40). Two of the identiﬁed mutations,
p.Tyr481His and p.Gly482Arg, affect highly con-
served residues within this channel domain (Fig. 6).
Our heterologous expression studies of WT HCN4
with mutant HCN4 carrying, respectively, the
p.Tyr481His and the p.Gly482Arg mutations (reﬂect-
ing the heterozygous situation in mutation carriers),
uncovered a large negative shift of the voltage
dependence of activation compared with the ex-
pression of only WT channels. This ﬁnding is in
agreement with previous observations for 2 other
pore-region HCN4 mutations, namely p.Gly480Arg
(4) and p.Ala485Val (3), both located close to
p.Tyr481His and p.Gly482Arg, indicating the impor-
tance of the pore region of the channel for the voltage
dependence of activation. The other mutation we
identiﬁed, p.Ala414Gly, which is also evolutionarily
highly conserved, is the ﬁrst mutation described in
the S4–S5 linker. The cytoplasmic S4–S5 linker of
HCN channels is thought to play a role in voltage-
activated gating (42). Consistent with this hypothe-
sis, p.Ala414Gly resulted in a negative shift of the
voltage dependence of activation. The shifts of the
activation voltage dependence toward more negative
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FIGURE 7 HCN4 Mutations Shift the Voltage Dependency of Activation Towards More Negative Potentials
(A) Voltage clamp protocol (top panel) and typical wild-type (WT) HCN4 current (bottom panel). Inset, superimposed tail currents. (B) Voltage
dependency of activation (left panel). The dashed curves are the Boltzmann ﬁts to the data, and the gray area represents the voltage range of
diastolic depolarization of human sinoatrial node (SAN) pacemaker cells. Average half-maximum activation voltage (V1/2) and slope factor (k)
(right panels). Note that the mutant channels activate at more negative potentials (68.4  2.8, 92.3  5.3, 112.3  3.5, and 107.1  6.1
for WT [n ¼ 11], WTþp.Ala414Gly [n ¼ 9], WTþp.Tyr481His [n ¼ 8], and WTþp.Gly482Arg [n ¼ 7], respectively). (C) Current-voltage
relationships of WT and mutant HCN4 channels (left panel). The gray area represents the voltage range of diastolic depolarization of human
SAN pacemaker cells. Average current density at 60 and 50 mV (right panels). Note that current densities in mutant channels are
signiﬁcantly smaller compared with WT HCN4.
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753potentials observed for the 3 mutations result in a
signiﬁcantly lower HCN4 current density in the po-
tential range of the diastolic depolarization (i.e., the
action potential phase responsible for the sponta-
neous activity of SAN cells). The very small inwardcurrent that drives the diastolic depolarization is the
net result of a complex interaction of a large number
of inward and outward currents, including the
inwardly directed HCN4-mediated current underlying
If (40). The reduced If observed for the 3 mutations is
CENTRAL ILLUSTRATION HCN4 Mutations in Bradycardia and LVNC
Location of HCN4 mutations causing the combined clinical presentation of bradycardia
and left ventricular noncompaction (LVNC). The 3 mutations decrease HCN4 current
density in the potential range of the diastolic depolarization in sinoatrial cells causing
the bradycardia. The mechanism underlying the LVNC remains unknown. We hypoth-
esize that LVNC as a result of mutation in the HCN4 gene may arise from a congenital
signaling defect or could occur as a consequence of cardiac remodeling in response to
the lower heart rate.
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754thus compatible with the clinically observed
bradycardia.
Although the involvement of HCN4 mutations
in bradycardia is in line with the established role
of HCN4 in cardiac pacing, the mechanism under-
lying the LVNC observed in the described families
is unclear. We formed 2 possible hypotheses that
will require further testing (Central Illustration):
1. LVNC may be congenital and the direct result of
the HCN4 mutations in these families. In humans,
the trabecular myocardium compacts around 8
weeks of gestation, following ventricular septation
(43). In mice, at this developmental stage, Hcn4 is
expressed within the SAN (44) and in humans also
is detectable in the trabecular (subendocardial)
layer, although at a low level in comparison with
that of the SAN (45). Furthermore, a recent
study demonstrated that Hcn4 is expressed in an
early progenitor pool of cells that ultimately
gives rise to the left ventricle (both compact and
trabecular) (46). The presence of HCN4 in pre-
cursors of the ventricular wall myocardium
would allow for a signaling function of HCN4 in
the process of normal compaction of the human
fetal ventricles.
2. A second hypothesis may be that the observed
LVNC is an acquired feature in response to sinus
bradycardia, as an adaptive remodeling to enableincreased stroke volume and improved cardiac ox-
ygen uptake. This hypothesis is supported by the
fact that mild trabeculations are a physiological
response to exercise (47). Possible future studies
could entail longitudinal studies in patients taking
the If-blocker ivabradine—a common angina pecto-
ris medication for which bradycardia is a common
side effect—to check the possible development of
LVNC.
The possibility that LVNC may be an incidental
ﬁnding seems unlikely, given the very low frequency
in the population (0.05%) (48) and the consistent
observation of this feature in all the HCN4 mutation
carriers across all families, whereas it was absent in
the noncarriers. This study will further aid the diag-
nostic challenges associated with LVNC. Other car-
diac complications are present in the families,
including myxoid mitral valve, atrial ﬁbrillation, left
ventricular hypertrophy, and sudden cardiac arrest.
The latter occurred in 2 individuals from family A,
one with and the other without the familial HCN4
mutation. The occurrence of OHCA in the individual
who tested negative for the familial HCN4 mutation
could point to an additional genetic defect in the
family. Screening of a large panel of genes associated
with primary electrical disease or cardiomyopathy in
this individual, however, did not identify any puta-
tive mutation (data not shown).
Cardiac ion channel mutations thus far have been
mainly identiﬁed in association with arrhythmic
disorders of the heart, attributed to primary
arrhythmia syndromes without myocardial abnor-
malities. However, in line with the ﬁndings pre-
sented in this study, evidence is now accumulating
that primary channelopathies also can be associated
with the development of myocardial structural ab-
normalities (49,50).
STUDY LIMITATIONS. In this study, although the
genetic evidence for the involvement of the HCN4
mutations in the combined bradycardia–LVNC phe-
notype is very strong, and the electrophysiological
data provide strong evidence for causality of the
HCN4 mutations in the pathogenesis of the observed
bradycardia, the mechanism whereby HCN4 muta-
tions lead to LVNC remains unknown.
CONCLUSIONS
For the ﬁrst time, we link mutations in HCN4 to a
combined phenotype of bradycardia and LVNC. Our
ﬁndings implicate mutations in this ion channel gene
in cardiac structural abnormalities in addition to si-
nus bradycardia.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The combined
cardiac phenotype of sinus bradycardia in association with left
ventricular noncompaction cardiomyopathy (LVNC) is now linked
to mutations in HCN4 in multiple families.
TRANSLATIONAL OUTLOOK 1: Although the pathogenetic
mechanism whereby HCN4 mutations cause bradycardia is
established, additional research is needed to uncover the
mechanism by which such mutations cause LVNC.
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